Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042762 | 1.00 | HTR3A (0.60) | HTR3ASLC18A3SIGMAR1JAK3HTR2C | |
| Hydrochloric Acid SCHEMBL3543860 | 0.98 | HTR3A (0.58) | HTR3ASLC18A3SIGMAR1JAK3HTR2C | |
| Hydrochloric Acid SCHEMBL5874037 | 0.98 | HTR3A (0.58) | HTR3ASLC18A3SIGMAR1JAK3HTR2C | |
| SCHEMBL3255979 | 0.90 | HTR3A (0.48) | HTR3A | |
| SCHEMBL373584 | 0.87 | SLC18A3 (0.61) | HTR3ASLC18A3SIGMAR1HTR2CMKNK1 | |
| Hydrochloric Acid SCHEMBL27942946 | 0.85 | SLC18A3 (0.59) | HTR3ASLC18A3SIGMAR1HTR2CMKNK1 | |
| Hydrochloric Acid SCHEMBL31401438 | 0.82 | SLC18A3 (0.52) | HTR3ASLC18A3SIGMAR1HTR2CMKNK1 | |
| SCHEMBL2720916 | 0.82 | CHRNB4 (0.44) | HTR3A | |
| Hydrochloric Acid SCHEMBL8128177 | 0.80 | CHRNB4 (0.43) | HTR3A | |
| Hydrochloric Acid SCHEMBL1742230 | 0.80 | CHRNB4 (0.43) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| CN-112457362-B | Halogenated tetracyclic triterpene derivative and preparation and application thereof | 上海青东生物科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| CN-109311860-B | Xanthone derivatives for the treatment or prevention of hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3464278-B1 | XANTHONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| EP-3573987-B1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2021-03-10 | — | — | EP | disclosed |
| CN-112457362-A | Halogenated tetracyclic triterpene derivative and preparation and application thereof | 上海青玄生物科技有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-20030171354-A1 | Compounds | ASTRAZENECA AB (SE) | 2003-09-11 | — | — | US | disclosed |
| CN-1098264-C | Substituted 4- (1H-benzimidazol-2-yl-amino) piperidines for the treatment of allergic diseases | AVENTIS PHARMA INC (US) | 2003-01-08 | — | — | CN | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002094789-A1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
| US-5622966-A | BACTERICIDES TREATING INFECTIONS | WARNER-LAMBERT COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5446044-A | Bactericides | WARNER-LAMBERT COMPANY (US) | 1995-08-29 | — | — | US | disclosed |
| US-5384407-A | Pyrrolidine compounds | WARNER-LAMBERT COMPANY (US) | 1995-01-24 | — | — | US | disclosed |
| US-5342844-A | 7-substituted quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| WO-1993016077-A1 | 7-SUBSTITUTED QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-08-19 | — | — | WO | disclosed |
| US-5221676-A | 7-substituted quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1993-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | HTR3A 133/4885SLC18A3 1402/4885SIGMAR1 633/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | HTR3A 2661/4885SLC18A3 3983/4885SIGMAR1 3726/4885 |
| US-20030171354-A1 | Compounds | GNRHR, LHCGR, FSHR | HTR3A 707/4885SLC18A3 875/4885SIGMAR1 1956/4885 |
| US-10752640-B2 | Compounds active towards bromodomains | BRD4, BRD3, BRDT | HTR3A 3354/4885SLC18A3 4565/4885SIGMAR1 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.